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Abstract
Sarcomas are cancers of the bone and soft tissue often defined by their gene fusions. However, the 
timing, context, and processes by which these pathogenic fusions arise are unknown. We explored 
this in Ewing sarcoma, a cancer driven by EWSR1-ETS fusions, with very few cooperating 
mutations. Combining whole-genome sequencing with enhanced informatics, we found that the 
EWSR1-ETS fusion arose from striking rearrangement clusters in 42% of cases (52/124). Notably, 
these were organized in loops that universally contained the fusion at their center, while also 
weaving up to 18 genes together with it. We found the same pattern of rearrangements in three 
additional types of sarcoma. From these data, we define a new signature for sarcoma fusions that 
precedes other somatic changes, in the earliest replicating DNA of the genome. This dramatic, 
sudden process impinges on many genes – generating multiple coding changes that profoundly 
affect the transcriptome, with the disease-defining gene fusion at its core. These rearrangement 
loops arise in an early ES clone from which both the primary tumor and the lethal relapse 
emerged, and then evolved in parallel until clinically detected.
Genomic rearrangements (structural variants) are a ubiquitous source of somatic mutation in 
human cancer. They arise from breaks in chromosomes, which are aberrantly rejoined. 
Rearrangements may occur in isolation or in the context of complex genomic catastrophes 
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that shatter (chromothripsis (1)) or join chromosomes in chains or loop-structures 
(chromoplexy (2)). Rearrangements can generate cancer-driving mutations through several 
mechanisms, including the formation of gene fusions. Typically, fusions are fashioned by 
translocations that are often reciprocal. An exception is the prostate cancer fusion gene, 
TMPRSS2–ERG, that can occur in the context of chromoplexy(2).
Oncogenic gene fusions are particularly common in leukemia and bone and soft tissue 
tumors (3), often acting as the sole driver mutation and delineating clinically relevant tumor 
entities and subgroups. In leukemia, RAG-mediated recombination has been identified as the 
leading mutational process that creates canonical gene fusions and drives oncogenesis 
through translocations and deletions (4). Here, we sought to investigate processes and timing 
of oncogenic fusions in human bone and soft tissue tumors.
The starting point of our investigation was Ewing sarcoma (ES), a bone and soft tissue 
cancer predominantly diagnosed in adolescents and young adults. It represents the 
prototypical fusion-driven sarcoma, defined by fusions between EWSR1 and an ETS 
transcription factor, including FLI1 and ERG (5). Although the downstream consequences of 
EWS-ETS are well established (6), the timing and mechanism by which it arises are 
unknown.
Burden and signatures of small mutations in Ewing sarcoma
We sequenced the gene-containing portions of, or whole genomes of 50 ES tumors and their 
matched normal DNA (complete sequencing details in table S1). We used a conventional 
analysis pipeline to call somatic substitutions and rearrangements, with additional custom 
software to remove recurrent artefacts and sources of false positives (see Methods and fig. 
S1). Overall, and consistent with previous reports (7–10), the ES genome is genetically 
quiet, with few somatic substitutions identified (Median: <1 Mut/Mb; Fig. 1A). The number 
of small coding mutations was also low.
We next asked if the collection of all mutations, when considered together, could help 
highlight consistent mutagenic processes in ES. We extracted mutational signatures using an 
established method that allows for the discovery of new signatures. Despite their young age 
and quiet genomes, ES patients’ tumors contained at least seven distinct signatures, all of 
which matched patterns found in adult cancer (COSMIC # 1, 2, 5, 8, 13, 18 and 31; Fig. 1B, 
fig. S2A) (11, 12). Two of these (#1 and 5) were nearly universal, and associated with 
patient age. Signature 1 generated a steady rate of 7 mutations per Gb per year, which is 
similar to that of adult ovary and breast cancer (fig. S2B) (13). An overview of the somatic 
architecture and mutational signatures of each tumor in our discovery cohort is shown in Fig 
1A-C (left panels, Toronto Cohort).
Chromoplexy rearrangement loops are common in aggressive Ewing 
sarcoma
Having observed few small mutations, we then focused our attention on structural 
rearrangements. We applied a bespoke analysis tool to detect clustered rearrangements from 
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whole-genome data, defined as having an inter-rearrangement distance of <10 kbp (see 
Methods). Using a computational data structure that modeled adjacent breakpoints as 
vertices and inter-connected rearrangements as edges in a graph, we uncovered several 
distinct configurations of rearrangement clusters (Fig. 1D). As expected, one configuration 
of rearrangement clusters was a result of reciprocal rearrangements, where there is an equal 
exchange of genetic material and overlapping breakpoints. These were isolated 
rearrangements that occurred without additional breakpoints nearby. A second configuration, 
seen in 15/24 tumor genomes, was a distinctive pattern of focal clustered events with nearly 
overlapping junctions, organized as closed loops (distance < 30 bp; Fig. 1D, red 
distribution). That is, if one follows these complex rearrangements across their multiple 
constituent chromosomes, one is ultimately brought back to the point of departure. 
Importantly, the loops were nearly always centered on EWSR1-ETS (Fig. 1E). These 
abutting rearrangements that occur in a loop resemble a pattern of chromoplexy, akin to the 
loops of the prostate cancer fusion gene, TMPRSS2–ERG. Of note, the EWSR1-ERG fusion 
was always generated by a complex mechanism, whereas EWSR1-FLI1 arose with or 
without this mechanism (fig. S3A). This is likely due to the opposite gene orientation of 
EWSR1 relative to ERG on their respective chromosome arms. A simple two-chromosome 
break rearrangement cannot place the genes in the correct transcriptional orientation, 
necessitating more complex chromosomal rearrangements for fusion formation. Besides this, 
ERG and FLI1-driven chromoplexy were highly similar (fig. S3B).
In all cases, we resolved the breakpoints and found, primarily, positions consistent with 
‘Type I’ or ‘Type II’ ES (14). In the most complex case of chromoplexy, up to 18 genes were 
brought together with the canonical fusion on the same derivative chromosome (fig. S3C, the 
full list of genes affecting all samples is shown in fig. S3D). We validated chromoplectic 
looped rearrangements by deep sequencing or by cytogenetic analysis using standard G-
banding and spectral karyotyping (Methods and fig. S4). Using RNA sequencing, we found 
that chromoplectic loops universally disrupted the reciprocal fusion (FLI1-EWSR1); 52% of 
the cancers with simple rearrangements expressed the reciprocal fusion, but none of the 
chromoplectic tumors expressed it (n=27, fig. S5). For further validation of chromoplexy in 
ES, we re-analyzed a published, independent cohort of 100 ES genomes using our 
informatics pipeline (10). The somatic architecture and mutational signature of the 
validation cohort is shown in Fig. 1 (right panels, Validation Cohort). Both cohorts harbored 
copy number profiles consistent with previous reports (fig. S6)(10). With this series, the 
aggregated prevalence of chromoplectic EWSR1-ETS gene fusions was 42% (52/124).
The survival for relapsed ES is poor and new prognostic markers are needed. We evaluated 
the association between chromoplexy, patient outcomes, as well as known markers of worse 
prognosis. We found that higher overall genomic complexity, a marker of aggressive ES (10, 
15), was almost completely explained by chromoplectic rearrangements (Fig. 1F). In 
contrast, there was no difference in the burden of non-chromoplectic rearrangements. 
Similarly, TP53 mutations, another established marker of poor prognosis (10, 16), were 
enriched in chromoplexy ES (16% vs. 3%, p < 0.05). There was no enrichment for 
CDKN2A or STAG2 mutations (fig. S7). Finally, and consistent with the above, patients 
with chromoplexy ES were more likely to relapse (54% vs. 30%, p < 0.05), strongly 
suggesting that it marks a more aggressive variant of ES.
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Chromoplexy generates the key fusion in many cancer types
We next widened our search across four different benign and malignant bone and soft tissue 
tumor types, for which canonical gene fusions have been identified (table S2). We subjected 
13 tumors to high or low coverage whole genome sequencing, plus RNA sequencing where 
feasible. In three tumor types - chondromyxoid fibroma, synovial sarcoma, and phosphaturic 
mesenchymal tumors - we found that chromoplectic rearrangements (occurring in a similar 
looped formation) did indeed generate canonical gene fusions (Fig. 2). Furthermore, in one 
of the chondromyxoid fibroma cases, the fusion emerged from chromothripsis across seven 
different chromosomes (fig. S8, CMF #2). Chromothripsis was seen in five ES cases, of 
which four involved the canonical fusion. Taken together, these findings in human bone and 
soft tissue tumors show that canonical gene fusions are frequently caused by complex 
rearrangement processes, predominantly chromoplexy, but also chromothripsis.
We examined the microanatomy of chromoplexy fusion loops at base pair resolution, 
comparing ES to a published series of prostate cancers (2). EWSR1-ETS Ewing loops were 
less complex than TMPRSS2–ERG prostate cancer loops with fewer rearrangements and 
individual loops involved in their generation (2 to 10 rearrangements in 1- 2 loops compared 
with up to 130 rearrangements in up to 25 loops in prostate cancer). This may be a 
consequence of the ES genome having a shorter time frame to mutate compared to prostate 
cancer patients. Consistent with this proposition, multiple independent chromoplexy loops 
can exist in older prostate cancers, compared to the one simple loop seen in ES (17). In 
contrast to ES, where chromoplexy is virtually synonymous with the disease-defining fusion, 
several chromoplexy fusion loops occur in prostate cancer without necessarily forming the 
TMPRSS2–ERG fusion. When a loop was present in ES, it almost always generated the 
EWSR1-ETS fusion (47/52 cases, 90%) (Fig. 3A-B, fig. S9 and S10).
Significant transcriptional disruptions are associated with chromoplexy
These loops also led to targeted disruptions or fusions between genes brought together 
directly through chromoplexy (n=168 gene disruptions and n=47 fusions; Fig. 3C). Given 
that chromoplexy appeared to mark an aggressive form of ES, we wondered if its gene 
expression program was globally different - above and beyond the immediate, focal, 
structural consequences listed above. We identified 504 differentially expressed genes in 
chromoplexy compared to simple ES (p < 0.001, Fig. 3D). Gene set enrichment analysis of 
well curated pathways (18), uncovered a significant enrichment of dysregulated genes in 
established cancer hallmark pathways (table S3).
Both prostate cancer and ES loops were characterized by focal intra-chromosomal 
rearrangements - deletion bridges (2) - that acted as local mediators of large-scale loops 
(illustrated in fig. S11). We found deletion bridges in ~60% (30/52) of chromoplectic ES. 
Unlike prostate cancer, more than a third of bridges are utilized in ES in a highly consistent 
manner. That is, if a deletion bridge was found in one component of the loop, it would occur 
on all chromosomes. For example, in sample 2226 we observed 13 rearrangements, spanning 
three chromosomes, all of which involved deletion bridges. These bridged chromoplectic 
rearrangements fused EWSR1-FLI1, and disrupted the neighboring gene, AP1B1, as well as 
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the known cancer gene, ARID1B. Thus, deletion bridges can create further oncogenic 
disruptions.
We also observed a remarkable pattern of splicing, whereby the transcriptional machinery 
further refined the looped rearrangements found in the genome. In chondromyxoid fibromas 
with chromoplectic GRM1 fusions (3/4 cases), the rearrangement breakpoint did not 
actually reside within the GRM1 gene body. Rather, the breakpoint was instead found in the 
upstream gene, SHPRH, within a narrow window (fig. S8). Thus, chromoplexy plus 
conventional splicing leads to the promoter swap that is characteristic of this cancer (see 
(19)). Interestingly, we also observed the transcriptional generation of gene fusions in ES. 
Examination of the transcriptomic consequences of loops showed that genes that were 
unconnected at the DNA level were brought together, in cis, at the mRNA level. This 
included examples of the EWSR1-ETS fusion itself (Fig. 3D, fig. S12). In the cases reported 
here, no direct rearrangement links EWSR1 and FLI1, however they are linked via two 
rearrangements to a third locus. In this way, chromoplexy generates the canonical fusion 
driver via a chromoplexy scaffolding event.
Chromoplexy is among the primary, clonal, mutations in Ewing sarcoma, 
and enriched in early-replicating regions of the genome
Our next line of enquiry examined the timing of chromoplexy rearrangements in tumor 
evolution. Chromoplexy may arise from a one-off sudden event, generating many 
breakpoints simultaneously, or through step-wise progressive bursts of mutations in 
succession (2). To differentiate between these two modes of evolution, we used DNA copy 
number profiling associated with the breakpoints of chromoplexy rearrangements to assess 
the copy number of neochromosomes. A low number of copy number state (three or fewer) 
is associated with a one-off mutational event because breakage and ligation can only involve 
a small number of chromosomes inside a cell at any given time (20, 21). In contrast, 
stepwise progression would result in multiple copy number states due to the possibility of 
copy number alterations arising within older copy number alterations. Chromoplectic 
breakpoints involve many chromosomes and are not associated with any copy number 
alterations (fig. S13). That is, these looped rearrangements across the genome are balanced. 
In addition, using a novel algorithm, we found that the allele frequency of chromoplectic 
breakpoints was higher than that of simple structural rearrangements, providing further 
evidence that these breakpoints occurred together and early in tumor development (Methods 
and fig. S14). Given their extremely tight clustering, low number of copy number state 
transitions, and consistent clonal variant allele frequency, EWSR1-ETS loops are likely to 
have arisen from singular bursts of rearrrangements.
We then examined whether genomic regions of loop breakpoints share genomic properties 
predisposing these regions to simultaneous rearrangement. We performed a comprehensive 
analysis of 38 genomic properties, including adjacency to histone marks, association with 
replication timing, as well as proximity to genes, repetitive or transposable elements (table 
S4). Of these properties, early replicating DNA, and features consistent with this, were the 
most strongly associated with chromoplexy loops (p < 1.0 x 10-36, Fig. 4A-B). In stark 
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contrast, neither non-looped simple breakpoints of ES, nor simulated simple breakpoints, 
were significantly associated with replication timing, or indeed any other feature (see 
Methods). Replication timing is known to be strongly correlated with gene activity, 
chromatin accessibility and nuclear position (22). Accordingly, chromoplectic breakpoint 
positions were also strongly associated with high gene density and high GC content (fig. 
S15A). Conversely, lamina-associated domains, enriched in late-replication regions and 
repressive chromatin environments, were found to be negatively associated with 
chromoplectic rearrangements. These significant associations were upheld when breakpoints 
directly residing in EWS, FLI1 or ERG were removed from the analyses. Remarkably, the 
same associations were found for looped rearrangements of ETS+ prostate cancers, but not 
for simple prostate cancer rearrangements (fig. S15B). Of further interest, we noted that the 
genes impacted by chromoplexy, were amongst the most highly expressed in ES, across all 
patients (top 20%; fig. S16). Most expressed genes are found in early replicating DNA (23). 
These data are consistent with the proposed model of chromoplexy where DNA is co-
localized in transcription hubs allowing for multiple genes from many chromosomes to be 
broken, shuffled and aberrantly ligated, as proposed (2).
Mutation Patterns of Relapsed and Metastatic Ewing sarcoma
Taken together, we have seen that chromoplexy arises early in the evolutionary history of 
ES, through a replication-associated mechanism, portending a worse prognosis and possible 
relapse. However, the genetic makeup of relapsed ES is unknown, since standard of care for 
ES does not typically involve re-biopsy of the cancer when the disease returns or has 
metastasized. Therefore, whether further mutations - chromoplectic or otherwise - emerge at 
relapse is unknown, since very few samples have been available. However, re-biopsies were 
performed for a small number of our patients, which we profiled by WGS and performed 
full mutation and signature analysis (Fig. 5A). Strikingly, every relapse or metastatic tumor 
contained the chromoplexy-associated fusion, whether it was from a metastasis at the time of 
diagnosis or a relapse arising later (Fig. 5B). The pattern of point mutations was also 
distinct. There was an enrichment of signatures 8 and/or 18, in addition to the clock-like 
signature seen at diagnosis, suggesting that new processes drive relapse and metastatic ES 
(Fig. 5B). For example, in one patient’s tumor we found a striking increase of COSMIC 
Signature 31, which has been recently associated with exposure to platinum therapy in 
chronic myelomonocytic leukemia (24). Notably, our patient had been treated with 
carboplatin for an early retinoblastoma three years prior to their ES. At least three other 
patients in the validation cohort had a similar signature in their ES, which we believe were 
also treatment induced (Fig. 1B).
Early divergence and parallel evolution of Ewing sarcoma tumors
The most commonly held model for progression of cancer is that a metastasis originates 
directly from the primary tumor - it may have acquired new mutations but, since it derived 
by linear clonal evolution, most of the properties of the primary will be found in the 
metastasis (25). A different model was suggested in ES, proposing that the metastasis 
diverged early, based on mutation data from two primary-metastasis pairs whose exomes 
were sequenced, although the timing of this divergence was not established (8). We 
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compared coding, non-coding and structural rearrangements across the genome within four 
ES pairs. As is the cases in most tumor types, relapse and metastatic ES tumors acquired 
many new mutations (average 50% private). A strikingly high number of clonal mutations 
from the primary were lost in the relapse (average 20%), confirming that the latter diverged 
early, evolving in parallel. For example, a disruptive clonal PTEN inversion was found in all 
tumor cells of one primary ES, but was absent from the relapse (Fig. 5C). We also confirmed 
the same model of parallel evolution in one additional primary-metastatic pair, profiled using 
microarrays (fig. S17). The clinical implication for this model is that one should also be 
searching for therapeutically targetable mutations arising in parallel to the primary ES, using 
methods like circulating tumor DNA, not necessarily in the primary tumor itself.
To determine when the divergence of the lethal clone occurred, we used the number of 
COSMIC Signature 1 mutations, which emerge at a steady rate in ES (see Methods and fig. 
S18). We first confirmed our approach by comparing the number Signature 1 mutations 
between established time intervals, such as the dates of diagnosis and recurrence. In all 
cases, the observed number of mutations was extremely close (75-90%) of what would be 
expected (fig. S18). Using the established rate, we calculated the amount of time between 
the divergence of the primary and relapse / metastatic tumors. Notably, the common ancestor 
in ES clonally diverges 1-2 years before diagnosis. Therefore, the cells that give rise to the 
primary and relapse tumor can exist in the patient years before diagnosis, providing a 
window for early cancer detection and surveillance. ES is often difficult to diagnose and 
time-to-diagnosis is notoriously long (26). These findings provide a plausible biological 
mechanism for this latency.
Discussion
Overall, our analyses have revealed rearrangement bursts (chromoplectic loops) as a source 
of gene fusion in human bone and soft tissue tumors. It is known that ES with complex 
karyotypes have worse prognosis, and here we show chromoplexy as the mechanism in 42% 
of tumors (27). It is possible that it is the chromoplectic tumor’s additional gene disruptions 
and fusions that contribute to this survival difference. Our whole genome data supports a 
model in which there is an early clone of ES, containing EWS-ETS and chromoplexy, 
arising at least 1 year pre-diagnosis, which gives rise to both the primary and metastatic or 
relapse tumors (Fig. 5D). Whether the bursts described here are chance events or driven by 
specific mutational processes, akin to RAG-machinery operative in leukemia, remains to be 
established. As an increasing and diverse number of tumor genome sequences become 
available, we may be able to define further rearrangement processes that underlie fusion 
genes and thus unravel the causes of fusion-driven human cancers.
Materials and Methods
Patient and sample collection
Ewing sarcoma tumor and matched blood samples were collected from the Hospital for Sick 
Children (SickKids) and Mount Sinai Hospital in Toronto, Canada in accordance with each 
institution’s Research Ethical Board (REB) guidelines. Detailed clinical information (age at 
presentation, gender, tumor site, stage, etc.) were obtained from the corresponding 
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institutional tumor banks (table S5). Overall, the patients’ clinical features and 
demographics were typical of Ewing sarcoma: the average age of diagnosis was 14.8 years 
(2.8 to 36.6 yrs.); the male to female ratio was 1.38:1; and 14 patients had relapsed, with 13 
having died from their disease. Additional samples (n=3) were also obtained from 
Universitätsklinikum Erlangen, Erlangen, Germany. All metastatic or relapse Ewing 
sarcoma tumors were collected from SickKids tumor bank or the SickKids clinical cancer 
sequencing program (KiCS). Detailed information on KiCS is available at https://
www.kicsprogram.com.
Of the 25 high-coverage genomes sequenced, EWSR1-ETS fusions were detected in all 
patients except for a 37-year-old who was instead found to have a FUS-ERG translocation. 
This patient’s gene expression profile (by RNA-Seq) was also discrepant and so they were 
removed from subsequent analyses (fig. S19). One additional genome was removed due to 
poor sequencing quality. We also performed low pass (~10X) rearrangement screens on 19 
ES samples. However, as we required breakpoint resolution, all but one of the rearrangement 
screens were excluded from this study due to insufficient coverage (see Table S1, orange 
row). Taken together, our discovery cohort consisted of 23 standard genomes (30-60X) and 
one rearrangement screen genome (20X). The validation cohort consisted of 119 tumor-
normal samples sequenced by Tirode F. et al (10), which we downloaded from the European 
Genome-phenome Archive (accessions: EGAS00001000855 and EGAS00001000839). Of 
these, 19 patient samples were omitted either because the EWSR1-ETS fusion was not 
detected by our pipeline and manual inspection of the aligned reads, or because they 
harbored an excess of artefactual small inversions or deletions.
Code availability
Custom code described here is available at github.com/shlienlab
High-throughput sequencing and alignment
Exome, genome and transcriptome (RNA-Seq) sequencing were performed using 
established protocols on Illumina instruments. For exome and genomes, paired-end FASTQ 
files were aligned to the human genome (hg19/GRCh37) using BWA-MEM (v.0.7.8), Picard 
MarkDuplicates (v.1.108) was used to mark PCR duplicates. Indel realignment and base 
quality scores were recalibrated using the Genome Analysis Toolkit (v.2.8.1).
Detection of high quality somatic substitutions and rearrangements
We detected somatic mutations using established tools (MuTect2 (part of GATK v.3.5) (28) 
and Delly v.0.7.1 (29)). To evaluate and validate our WGS substitution pipeline, we used a 
“gold standard” cancer genome tumor/normal dataset, COLO829 (30). Using this somatic 
reference standard, we determined our precision to be 0.885 and our sensitivity to be 0.971. 
Copy-number was detected for genomes and rearrangement screens using BIC-seq v.1.2.1 
(31). When no matched normal was available (in the case of rearrangement screens), an 
Ewing sarcoma normal was used. We then developed custom code to increase specificity of 
putative substitution and rearrangement detection, as follows:
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1. Somatic and Depth Filter. No mutation should exist in the matched-normal 
sequence. For substitutions, we removed common single-nucleotide 
polymorphisms (SNPs) as previously described (32) and a required >10X 
coverage at the mutated locus (10 kb window), in both tumor and normal. For 
rearrangements, this filter required >= 4 discordant read-pairs in the tumor. We 
then directly interrogated the normal BAM file, at each putative somatic 
rearrangement; to ensure no germline variants existed near the breakpoint, on 
either side of the rearrangement.
2. Panel of Normals Filtering. To remove common germline variants, we created a 
panel of normal, non-neoplastic, samples that had been sequenced using the 
same technology and to a similar depth of coverage (n=133). We removed any 
putative substitutions or rearrangements if present in ≥ 2 normals. For 
rearrangements, breakpoints must exist on both sides of the junction within a 1 
kb window. We found that as we increased the number of normals in our panel, 
our specificity increased (fig. S1C).
3. Quality Control Filtering. Putative rearrangements were removed if supported by 
reads with MAPQ < 30. Both putative rearrangements and substitutions were 
also removed if they met any two of the following criteria:
A. Non-unique mapping. <70% of the reads at the locus map uniquely.
B. Multi-mapping clusters. At the same locus (200 bp up and 
downstream), a pattern of multiple overlapping groups of discordant 
reads whose paired-ends align to different chromosomes (> 3 reads in 
each group, mapping to > 4 chromosomes). Seen in both the tumor and 
paired normal.
C. High depth. Excessively high depth alignments in difficult to align 
regions of the genome, as described (33). We apply a maximum depth 
threshold of d+4*sqrt (d), where d is the average normal mean read 
depth of the chromosome in the corresponding normal.
D. Low-complexity regions. Overlap with a highly repetitive sequence 
(using DUST (34) with score > 60).
Mutation signature extractions and analysis
First, a de novo extraction was performed on the catalogue of Ewing sarcoma point 
mutations to produce novel consensus mutational signatures. These signatures were 
deciphered using a previously described computational framework that optimally explains 
the proportion of each mutation type found in the catalogue and then estimates the 
contribution of each signature to the mutation catalogue (11). Overall, we identified 11 
consensus mutational signatures. 4 of these signatures were previously found to be attributed 
to sequencing artefacts. We then compared our true consensus mutational signatures to the 
previously curated COSMIC list and quantified their similarity using a cosine similarity as 
previously done (13). We report > 0.9 cosine similarity between the Ewing signatures and 
the COSMIC list.
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Validation by targeted custom-capture sequencing
A custom targeted-capture enrichment system was designed to capture 1 Mb of DNA 
(Nextera, Illumina) with custom probes for the whole of EWSR1, FLI1, and ERG genes as 
well as the exons of TP53, STAG2 and ATRX. We also targeted known complex breakpoints 
from the discovery cohort, achieving between 900 to 1000-fold coverage. We reasoned that 
paired end sequencing would capture any locus joined to the three core genes, even if the 
panel did not specifically target it. In this way, we validated rearrangements in samples 
where chromoplexy was already known from the whole genome, and uncovered new 
instances in samples that had not been whole genome sequenced (n=7 and 4, respectively). 
Each tumor had three or four rearrangements validated using the panel. All had the same 
breakpoint (as found by the whole genome sequence) and were found to harbour looped 
rearrangements are on the same derivative chromosomes.
Validation by FISH, G-banding or Spectral Karyotyping
We further validated these looped rearrangements by karyotyping Ewing sarcomas using 
standard G-banding as well as spectral karyotyping (n=17 and 3; fig. S4). By cytogenetics 
we found additional complexity - beyond the canonical chr22-chr11 translocation - in eight 
cases. Of these, six tumors had been sequenced and found to be complex. Additionally, there 
were 5 cases for which chromoplexy was detected by genome sequencing yet not found by 
cytogenetics techniques, indicating that routine cytogenetics may miss chromosomal 
complexity present in these genomes due to the nature of these submicroscopic complexities 
(fig. S20).
Timing of rearrangements using breakpoint allele fraction
To determine the timing of the chromoplectic loops, we developed a tool to accurately 
measure the breakpoint allele fraction (BAF) of each rearrangement. The BAF is the 
proportion of reads containing a rearrangement breakpoint divided by the total number of 
reads, analogous to the variant allele fraction (VAF) for point mutations (illustrated in fig. 
S14A). This is analogous to the variant allele frequency of substitution mutations and, 
similarly, can be used to infer the relative order of rearrangement mutations. The tool 
accurately counts all reads supporting each rearrangement, even if these had not been used to 
nominate the rearrangement in the first place. From the raw aligned reads, we first collected 
all split reads near the breakpoint (within 20 bp) from one side of the rearrangement. Next, 
we extracted the clipped sequence (i.e. the non-aligned portion) from these reads and 
attempted to map it to the other side of the rearrangement (within 70 bp of the breakpoint) 
using a Smith-Waterman algorithm (35). Clipped sequences shorter than 5 bp were 
discarded, as were those that failed to map to the other side of the rearrangement (<= 80% 
similarity). Since the retained sequences can map at slightly different position, due to 
microhomology near the breakpoint, we considered all those close to one another as 
supportive of the same rearrangement. Overall, we found that most rearrangements are 
supported by re-mapped reads that less than 10 bp apart. Finally, the total number of split 
and realigned reads were divided by the average coverage between the two breakpoints per 
side of each rearrangement. This allowed us to arrive at an accurate measure of the 
breakpoint allele fraction. To validate our tool, we applied it to a curated list of known 
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polymorphic copy number variants (CNVs) (36). As expected, the BAF of germline CNV 
deletions followed a bimodal distribution with peaks at 0.5 and 1.0, for heterozygous and 
homozygous rearrangements, respectively (fig. S14B, green line). We then compared the 
BAF of somatic rearrangements in chains to those without. Chained rearrangements had 
higher BAFs than simple structural variants (fig. S14B, red vs blue line), confirming that 
chromoplectic rearrangements are in fact earlier.
Detection of Breakpoint Clusters of Chained Rearrangements
Using their inter-breakpoint distance, we identified rearrangements within 10 kbp of one 
another. Using these, we created an undirected graph in which two rearrangement 
breakpoints within 10 kbp of one another (a breakpoint cluster) were represented as a vertex 
and connected to other breakpoint clusters (rearrangements are edges in the graph). We 
selected connected components of the graph, and identified components with greater than 
one vertex as inter-connected rearrangements. In most of our cases, these interconnected 
rearrangements formed chains or loops, where one could follow the edges around the graph 
and return to the initial vertex of departure. These were further filtered for reciprocal 
rearrangements or overlapping intra-chromosomal rearrangements. Chromoplexy 
rearrangements were validated by manual inspection and using the ChainFinder algorithm 
(2).
Association of Rearrangements with Genomic Features
We formally evaluated the association of rearrangement position with 38 properties of the 
human genomes (table S4). We separately evaluated these each of these associations in 1 kb 
bins across the genome. Feature density properties were calculated as densities in various 
sliding windows (1kb, 10 kb, 100kb, 1 MB) centered on each 1 kb bin or as the log2 
distance, as indicated in table S4. The positions of Ewing sarcoma rearrangements were 
compared to million random positions that had been uniformly sampled from regions of the 
genome where confident genotypes could be determined (i.e. the “callable” genome). We 
limited our analysis to chromosomes 1 to 22 and X. To test for significant associations 
between our rearrangements and these genomic properties, we performed a Mann Whitney 
U test and Benjamin and Hochberg FDR correction to raw p-values. We used the Cohen’s d 
metric to determine the effect size between the two groups to account for differences in 
sample size. We applied an absolute Cohen’s d cut-off of 0.3, a medium effect size (37, 38). 
Genomic properties were considered significantly different between rearrangements and 
random positions if absolute (d) >= 0.3 and the corrected p < 0.05.
Detection of Gene Fusions
We detected gene fusions in regions of genomic complexity using an approach that 
integrates multiple independent fusion algorithms, and then removes those found in normal 
tissue (Fuligni et al., Under preparation). Putative fusions were validated by de novo 
assembly. A total of 1277 normal (non-neoplastic) samples from 43 different tissues were 
obtained from the NHGRI GTEx consortium (database version 4) and used to remove 
artefacts. All fusions were visually inspected if one or both genes involved chromoplexy or 
were adjacent (up to 1 Mbp). Fusions were further filtered by quality of the realigned 
transcript, breakpoint coverage and gene expression.
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Detection of Gene Expression
Gene expression for fusions, differential gene expression analysis, and principal component 
analysis was performed using HT-Seq (39) to count the reads aligning to every gene. PCR 
duplicates and reads mapping to ribosomal RNA, miRNA and small nucleolar RNA were 
removed. We used Trimmed Mean of M-value (TMM) method in the EdgeR package to 
perform normalization on genes with at least 1 read per million bases in at least 3 samples 
(40, 41). Differential expression analysis in chromoplexy vs non-chromoplexy samples was 
performed using a Generalized Linear Model (GLM) likelihood ratio test, taking in 
consideration different sources of variation like batch, gender and age. P-values for GLM 
test were adjusted for multiple testing using the Benjamini and Hochberg method for 
controlling the False Discovery Rate (FDR). Differentially expressed genes in chromoplexy 
vs non-chromoplexy were considered statistically significant if FDR <= 0.05 and absolute 
value of log(Fold Change) >=1. Pathway analysis was performed on genes differentially 
expressed in samples with and without chromoplexy using Gene Set Enrichment Analysis 
(GSEA) software (javaGSEA v2.2.4). Cancer gene signatures were selected from the 
hallmark collection from the Molecular Signature DataBase (MsigDB)(18). Enrichment 
scores for the hallmark pathways were considered statistically significant if FDR < 0.01.
Evaluation of Replication Timing in Prostate Cancer Rearrangements
We obtained prostate cancer rearrangements, including chained and others, from the Baca et 
al. publication (Supplemental table S3C and S5 from (2)). Samples were annotated as ‘ETS
+’ or ‘ETS-’ using Supplementary Table 1. ETS+ fusions include any ETS fusion detected 
by sequencing (including ERG and ETV1). Using this list we performed the same test for 
genomic property enrichment as we did in Ewing sarcomas.
Molecular Inversion Probe (MIP) Microarray
Raw MIP data from three additional primary-metastatic ES pairs were obtained from the 
Huntsman Cancer Institute, Salt Lake City, Utah (42). The original source material was 
clinically-archived, formalin-fixed paraffin-embedded (FFPE) scrolls that were retrieved 
from 3 individual patients diagnosed with ES. Primary tumor samples were from diagnostic 
biopsies prior to chemotherapy. The raw MIP data from the completed assay was loaded into 
Nexus Copy Number (BioDiscovery, Inc., El Segundo, CA) for copy number detection using 
default settings.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Disease-defining fusions in sarcoma frequently emerge by rearrangement burst, creating 
complex genomic loops and disrupting additional genes, in an early clone that may 
develop multiple years before diagnosis.
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Fig. 1. Mutation Landscape of Ewing Sarcoma.
The initial cohort consisted of 50 primary ES tumors, of which, 23 underwent whole 
genome sequencing (Toronto cohort, left). One rearrangement screen sample (sample 4462) 
is included in this figure. The validation cohort consisted of 100 ES whole-genomes from 
Tirode et al. 2014 (right). (A) Somatic mutation burden for Ewing sarcoma. The mutation 
burden of all genome samples are shown. Three outlier samples with >2 mutations/MB, are 
indicated by the red line. (B) Ewing sarcoma mutation signatures. Mutation signature 
analysis, defined by the proportion of 96 possible trinucleotides, identified common 
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mutation patterns in most samples (Age-associated, “clock-like” signature 1). Other 
signatures included #2, 5, 8, 13, 18, and 31. Signatures 2 and 13 are associated with the 
activity of the AID/APOBEC family of cytidine deaminase, while Signature 5 is also clock-
like in some cancers, but not ES (11, 13). Signatures 8 and 18 have an unknown molecular 
aetiology, however it has been suggested that Signature 18 is caused by reactive oxygen 
species (ROS)(43). Signature 31 is believed to be the result of exposure to platinum-based 
antineoplastic therapy (24).(C) Rearrangement profiles for Ewing sarcoma. Shown are 
the burden of deletions (blue), duplications (red), inversions (green) and translocations 
(purple) in individual ES genomes. Samples with chained complex rearrangements (looped 
rearrangements) are highlighted by red arrows (14/24 for Toronto, 38/100 for Validation, 
aggregated prevalence: 52/124). (D) Rearrangement breakpoint clusters. The aggregated 
density distributions of the genomic distance between consecutive rearrangement 
breakpoints are shown. Reciprocal breakpoints are close together (~102 bp) because there is 
an equal exchange of genetic material arising from a single break on each chromosome. 
Chromoplectic rearrangements (red) overlap this range due to the proximity breakpoints 
involved in looped rearrangements. Deletion bridge (DB) chromoplexy (purple) are looped 
rearrangement clusters in which a deletion spans two breakpoints, resulting in breakpoint 
distances that are farther apart (illustrated in fig. S11). Non-complex breakpoints (simple 
structural variants) are far apart (~108 bp). (E) Schematic diagram of chromoplexy fusion 
loops. Illustrative example of chromoplexy in Ewing sarcoma shows three chromosomes 
undergoing double-strand breakage, shuffling and religation in an aberrant configuration. 
This phenomenon generates the canonical fusion, EWSR1-FLI1 (ERG or ETV1) and 
disrupts a third locus, X, in a one-off burst of rearrangements. In reality, up to 8 
chromosomes may be disrupted in this looping pattern. A representative genome-wide 
Circos plots depicting genomic rearrangements in an Ewing sarcoma tumor (from the 
discovery cohort), which are organized in a loop. (F) Genomic correlates and clinical 
impact of looped rearrangements. In genomes without rearrangement loops, only simple 
structural variants (SSV) exist with an average rearrangement burden of 7 rearrangements/
sample. This rate is similar to the background SSV rate (determined by removing 
rearrangements involved in a loop) in genomes with rearrangement bursts (compare the two 
red lines). The additional complexity of looped rearrangements results in higher genomic 
instability in these tumors. The most common genomic alterations include somatic TP53 
mutations, which are rare, but enriched in patients with complex genomes (top pie chart, p < 
0.05). EWS-ERG fusions are also rare, as they represent 10% of all Ewing sarcoma 
diagnoses, however all EWS-ERG fusion Ewing tumors are either chomothriptic or 
chromoplectic (middle pie chart). Lastly, patients with complex genomes tend to relapse 
(bottom pie chart, p < 0.05). All the markers of aggressive disease (high genomic instability, 
somatic TP53 and relapse) are present in tumors with complex genomes.
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Fig. 2. Genomic Catastrophes are Common in Sarcomas.
Copy number profile for fusion-driven sarcomas with chromoplexy are shown. 
Rearrangements are colored red, and the loci with the canonical fusion are highlighted (blue 
box) and enlarged on the right. (A) Chrondromyxoid fibroma (CMF) with chromoplexy. 
The genomic breakpoint lies in the upstream SHPRH gene, while the BCLAF1-GRM1 
fusion was detected by RNA sequencing. Further complex CMFs, which also show a 
SHRPRH genomic breakpoint but GRM1 fusion, can be found in fig. S8. (B) Synovial 
sarcoma with chromoplexy. Chromoplexy generating the SS18-SSX1 pathognomonic 
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canonical fusion is shown. (C) Phosphaturic mesenchymal tumor (PMT) with 
chromoplexy. Genome sequencing of PMTs revealed deletion bridges occurring across the 
genome at chromoplectic loci, generating the canonical FN1-FGFR1 fusion.
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Fig. 3. Characterizing chromoplexy loops that generate EWSR1-ETS in ES.
(A) Patterns of looped rearrangements. Chromoplexy circos webs demonstrate that 
patterns of looped rearrangements are conserved across samples, while different genes or 
loci are affected in each cancer (black panels). In each web, individual samples are denoted 
using a different color (and named in the grey panel). In all cases, central to chromoplexy 
fusion loops were the key driver genes: EWSR1 (blue), FLI1 (green) and ERG (purple). The 
most frequent patterns of chromoplexy in Ewing sarcoma are those with a three-way looping 
structure as well as the presence of deletion bridges. For those with deletion bridges, “adj” 
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refers to adjacent loci affected. An enlarged Circos web can be found in fig. S9 for 
readability. Three samples have structures only involving EWSR1, FLI1 and adjacent loci. 
Sample 4004 has deletion bridge chromoplexy and is described in fig. S3C. (B) Summary 
of chromoplexy types. Bar chart showing the number of rearrangements in a loop (x-axis) 
and the number of samples with that rearrangement pattern. Other chromoplexy web 
structures can be found in fig. S10. (C) Transcriptional consequences of chromoplexy: 
gene expression. Volcano plot illustrating the differential gene expression in chromoplexy 
vs non-chromoplexy ES, revealing 504 differentially expressed genes. Points greater than 1 
or less than -1 and above the 1.3 (as indicated by the red lines) are genes that are 
significantly differentially expressed (blue dots). Red dots highlight genes that are 
differentially expressed and involved in a cancer hallmark pathway. (D) Transcriptional 
consequences of chromoplexy: gene disruptions and fusions. There are three mechanisms 
of gene dysregulation via RNA fusion when chromoplexy occurs. The first involves two 
genes (blue and purple boxes) brought together by chromoplectic rearrangements (black 
arrowed lines) leading to gene disruptions (top scenario) and novel inframe fusions (2nd 
from top scenario). This was detected in the 3/10 cases where there was genome 
(+chromoplexy) and transcriptome sequencing available. When RNA sequencing was not 
available, these are predicted to cause fusions (n=47, excluding the EWSR1-ETS driver) and 
gene disruptions by fusing genes in opposite transcriptional orientation or fusing a gene to 
an intergenic sequence (n=168). The second mechanism involves two chromoplexy genes 
brought together by a rearrangement at the genomic level, but one of the partner’s 
neighboring genes (green box) is transcriptionally fused to the other chromoplexy partner in 
its place (3rd from top scenario). This is also the predominant mechanism of GRM1 fusion 
generation in chrondromyxoid fibromas (fig. S8). Lastly, the final mechanism of gene 
dysregulation occurs when chromoplexy facilitates the production of a fusion by acting as a 
molecular scaffold (bottom scenario; illustrated in fig. S12). Two genes are both rearranged 
to a third locus (orange) and are then, transcriptionally, fused together. No direct genomic 
link exists between these two genes. These phenomena can only be detected if both whole-
genome and RNA-Seq are available.
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Fig. 4. Early Replicating DNA and Chromoplexy.
(A) Heatmap of genomic property associations. The genomic properties listed in 
supplementary table 4 were calculated for all rearrangements in both cohorts. Complex 
rearrangements (chromoplexy and chromothripsis), exclusively, are strongly associated with 
early replication timing, and other genomic features consistent with this feature (gene 
density, CpG density, Alu density etc.). Table values are indicative of FDR-corrected p-
values compared to a million random points in the genome. Blue highlights are indicative of 
a Cohen’s d equal to or greater than 0.3. Bold boxes indicate a positive (red, enrichment) or 
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negative (blue, depletion) association with the feature. All features were evaluated in 1 kb 
bins across the genome. For feature density metrics, associations were calculated in 1MB 
sliding windows centered in 1 kb bins. (B) Density distribution of the average wavelet-
smoothed signal and SNVs on representative chromosome. The average wavelet-
smoothed signal, of replication timing, is plotted for a subset of chromosome 6 to illustrate 
changes between early and late replication timing and the co-association with mutations in 
ES. The positional variation of replication timing across the chromosome is depicted as 
changes in density and color. Point mutations peak in late-replicating regions (dip in WSS, 
light purple), whereas complex rearrangements peak in regions of early replication timing 
(peak in WSS, dark purple).
Anderson et al. Page 24









Fig. 5. Mutation Signatures and Relapse and Metastatic ES Tumors.
(A) Prevalence of mutation signatures in relapse and metastatic tumors. Shared and 
private mutations for four primary-metastatic or relapse pairs are shown (first four columns). 
Signatures 1 and 5 are common throughout, with signature 5 contributing significantly to the 
mutations that arise at relapse. Signature 8 was also common throughout the cohort. One 
metastatic tumor (no paired primary) is also shown to have similar mutation signature 
patterns as other metastatic/relapse tumors. Lastly, a secondary Ewing sarcoma tumor to a 
primary retinoblastoma (germline RB1 mutation identified) was also sequenced in this 
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cohort. This patient harbored the rare Signature 31, which likely resulted from the patient’s 
prior exposure to carboplatin for their primary RB (only patient to receive this treatment in 
the Toronto cohort). (B) Phylogenetic trees of primary-relapse/metastatic ES. Using the 
shared and private mutations, we identified the mutational order in ES. Known cancer-driver 
mutations (IDH1, TP53 etc.) arise early (shared branches). (C) A clonal PTEN inversion. A 
PTEN inversion was found only in the primary and not in the relapse tissue, suggesting the 
inversion arose after early divergence of a common clonal ancestor. However, a pathogenic 
PTEN SNV can be found in the relapse tissue. Together, these point towards parallel, 
convergent evolution on this gene. (D) Proposed model of Ewing sarcoma tumor 
evolution. After birth, Signature 1 is operative in all somatic tissues throughout life. ES 
patients’ cells experience a replication-associated burst of rearrangements that generates the 
canonical fusion driver. Early somatic cancer gene mutations occur before clonal 
bifurcation. This occurs 1-2 years before an ES diagnosis, thus the cells that would give rise 
to the relapse existed years before diagnosis. Signature 5 contributes significantly to the 
number of mutations seen at relapse.
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